Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
2010
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
2009
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
2020 Standout
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
2014
Gout
2009 Standout
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
2006 Standout
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008
2011 Standout
Update on gout: new therapeutic strategies and options
2010
Gout
2016 Standout
The Inflammasomes
2010 Standout
Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population
2013
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
2013
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment
2010
A patient with arthritis, severe back pain, impaired wound healing, and perforated sigmoid colon
2006
Global epidemiology of gout: prevalence, incidence and risk factors
2015 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Febuxostat
2009
Gout
2021 Standout
Integrating mechanisms of pulmonary fibrosis
2011 Standout
Works of M.K. Reinders being referenced
Authors' reply: A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
2005
Rasburicase treatment in severe tophaceous gout: a novel therapeutic option
2005
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
2007
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout
2008
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
2008
Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?
2004